Marinus Pharmaceuticals Inc Revenue Growth Rates (MRNS), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Marinus Pharmaceuticals Inc   (NASDAQ: MRNS)
 

MRNS's Revenue Growth by Quarter and Year

Marinus Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MRNS Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December -
3rd Quarter September 8.54
2nd Quarter June 8.06
1st Quarter March 7.68
FY 24.28





MRNS Revenue third quarter 2024 Y/Y Growth Comment
Marinus Pharmaceuticals Inc reported Revenue increase of 16.36% year on year in the third quarter 2024, to $ 8.54 millions, this is lower than Marinus Pharmaceuticals Inc 's recent average Revenue surge of 117.66%.

Looking into third quarter 2024 results within Major Pharmaceutical Preparations industry 96 other companies have achieved higher Revenue growth. While Marinus Pharmaceuticals Inc ' s Revenue growth of 16.36% ranks overall at the positon no. 1014 in the third quarter 2024.


MRNS Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December - 0.42 % 371.05 % -1.94 %
3rd Quarter September 16.36 % 213.68 % -76.85 % 5847.06 %
2nd Quarter June 32.57 % 239.66 % -6.28 % -
1st Quarter March -26.01 % -26.85 % 683.98 % -
FY   - 21.62 % 65.99 % -

Financial Statements
Marinus Pharmaceuticals Inc 's third quarter 2024 Revenue $ 8.54 millions MRNS's Income Statement
Marinus Pharmaceuticals Inc 's third quarter 2023 Revenue $ 7.34 millions Quarterly MRNS's Income Statement


MRNS Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December - -2.04 % 205.98 % -84.97 %
3rd Quarter September 5.97 % 20.72 % 30.73 % 429.32 %
2nd Quarter June 4.95 % -41.43 % -87.39 % 5.52 %
1st Quarter March 6.82 % 44.97 % 833.55 % 16.77 %
FY (Year on Year)   - 21.62 % 65.99 % -


Back to MRNS Growth rate Comparisons >> Back to MRNS Growth rate Comparisons >>


Revenue third quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #97
Healthcare Sector #244
Overall #1014

Revenue Y/Y Growth Statistics
High Average Low
685.49 % 117.66 % -76.86 %
(Dec 31 2022)   (Mar 31 2023)
Revenue third quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #97
Healthcare Sector #244
Overall #1014
Revenue Y/Y Growth Statistics
High Average Low
685.49 % 117.66 % -76.86 %
(Dec 31 2022)   (Mar 31 2023)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Marinus Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
833.29 % 105.72 % -87.38 %
(Mar 31 2022)  


MRNS's III. Quarter Q/Q Revenue Comment
Marinus Pharmaceuticals Inc achieved in the III. Quarter 2024 below company average Revenue increase of 5.97% quarter on quarter, to $ 8.54 millions.

Within Major Pharmaceutical Preparations industry 96 other companies have achieved higher Revenue quarter on quarter growth. While Marinus Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 1179.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #97
Healthcare Sector #224
Overall #1179
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #97
Healthcare Sector #224
Overall #1179
Revenue Q/Q Growth Statistics
High Average Low
833.29 % 105.72 % -87.38 %
(Mar 31 2022)  


MRNS's III. Quarter Q/Q Revenue Comment
Marinus Pharmaceuticals Inc achieved in the III. Quarter 2024 below company average Revenue increase of 5.97% quarter on quarter, to $ 8.54 millions.

Within Major Pharmaceutical Preparations industry 96 other companies have achieved higher Revenue quarter on quarter growth. While Marinus Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 1179.


Marinus Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2024)		 12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Sep 30 2023)
Cumulative Revenue 12 Months Ending $ 31.47 $ 30.26 $ 28.29 $ 30.99 $ 30.96
Y / Y Revenue Growth (TTM) 1.63 % 16.56 % 30.53 % 21.63 % 56.08 %
Year on Year Revenue Growth Overall Ranking # 2566 # 2308 # 118 # 635 # 783
Seqeuential Revenue Change (TTM) 3.98 % 6.98 % -8.72 % 0.09 % 19.25 %
Seq. Revenue Growth (TTM) Overall Ranking # 628 # 2155 # 303 # 3326 # 1941


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2024 period, Marinus Pharmaceuticals Inc 's cumulative twelve months Revenue were $ 31 millions, company would post below average annual Revenue growth of 19.25% year on year, if the fiscal year would end at Sep 30 2024.
A slow-down in the Marinus Pharmaceuticals Inc 's Revenue growth from the 8.06% growth in Jun 30 2024.

In the Healthcare sector 399 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2308 to 2566.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 76
Healthcare Sector # 400
Overall # 2566

Revenue TTM Y/Y Growth Statistics
High Average Low
66.03 %
 25.22 %
-21.83 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 76
Sector # 171
S&P 500 # 628
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2024 period, Marinus Pharmaceuticals Inc 's cumulative twelve months Revenue were $ 31 millions, company would post below average annual Revenue growth of -21.83% year on year, if the fiscal year would end at Sep 30 2024.
A slow-down in the Marinus Pharmaceuticals Inc 's Revenue growth from the 8.06% growth in Jun 30 2024.

In the Healthcare sector 399 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2308 to 2566.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 76
Healthcare Sector # 400
Overall # 2566

Revenue TTM Y/Y Growth Statistics
High Average Low
66.03 %
25.22 %
-21.83 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 76
Sector # 171
S&P 500 # 628




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
MRNS's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Sep 30 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2024
Interpace Biosciences Inc 28.50%$ 28.501 millions
Biomarin Pharmaceutical Inc28.28%$ 28.282 millions
Beone Medicines Ltd 28.14%$ 28.136 millions
Zevra Therapeutics Inc 27.63%$ 27.634 millions
Scorpius Holdings inc 27.55%$ 27.552 millions
Adc Therapeutics Sa27.40%$ 27.399 millions
Cervomed Inc 27.07%$ 27.073 millions
Vericel Corporation27.04%$ 27.038 millions
Alphatec Holdings Inc 26.84%$ 26.838 millions
Cytomx Therapeutics Inc 26.71%$ 26.713 millions
Vycor Medical Inc 26.65%$ 26.653 millions
Twist Bioscience Corporation26.53%$ 26.535 millions
Neuropace Inc 25.79%$ 25.793 millions
Insulet Corporation25.70%$ 25.699 millions
P3 Health Partners Inc 25.58%$ 25.584 millions
Axonics Inc 25.57%$ 25.566 millions
Catalyst Pharmaceuticals Inc 25.33%$ 25.326 millions
Pro dex Inc 24.74%$ 24.745 millions
Neurocrine Biosciences Inc 24.72%$ 24.719 millions
Aurinia Pharmaceuticals Inc 24.32%$ 24.316 millions
Glaukos Corp23.92%$ 23.921 millions
Incyte Corporation23.81%$ 23.813 millions
Immunocore Holdings Plc23.74%$ 23.744 millions
Rapid Micro Biosystems Inc 23.74%$ 23.743 millions
Caredx Inc 23.35%$ 23.352 millions
Amgen Inc 23.18%$ 23.178 millions
Talkspace Inc 23.18%$ 23.176 millions
United Therapeutics Corporation22.89%$ 22.891 millions
Vanda Pharmaceuticals Inc 22.76%$ 22.764 millions
Cytokinetics Incorporated22.49%$ 22.487 millions


About Marinus Pharmaceuticals Inc Revenue Growth Rates (MRNS), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Marinus Pharmaceuticals Inc (CIK 1267813).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001558370-24-015315
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Marinus Pharmaceuticals Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.